You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

139 search results for: type 2 inflammation

The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Skin Barrier Dysfunction in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

FeNO as a Biomarker for <b>Type</b> <b>2</b> Asthma

expert video

FeNO as a Biomarker for Type 2 Asthma

16 min

Pulmonology

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.

CRSwNP: A Chronic <b>Type</b> <b>2</b> Inflammatory Disease

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

The Cycle of <b>Inflammation</b> in Adult Asthma

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients

Eosinophils as a Biomarker for <b>Type</b> <b>2</b> Asthma

expert video

Eosinophils as a Biomarker for Type 2 Asthma

15 min

Pulmonology

Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.

Inside the Hive: <b>Type</b> <b>2</b> Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

16 min

Dermatology

Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema

EAACI <b>2</b>0<b>2</b>3 | Pediatric <b>Type</b> <b>2</b> Inflammatory Disease Progression

expert video

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

40 min

Type 2 Inflammation

Dr. Leonard Bacharier and Profs. Oscar Palomares and Stephan Weidinger explore shared features of type 2 pathophysiology in AD, asthma, and EoE, and disease burden in pediatric patients

<b>Type</b> <b>2</b> Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

expert video

Type 2 Inflammatory Disease Trajectories: Unraveling Patterns of Disease Development and Burden in Pediatric Patients

15 min

Type 2 Inflammation

Dr. Leonard Bacharier presents potential disease trajectories and burden for pediatric patients with type 2 inflammatory diseases.

expert video

Cumulative Exposure to Corticosteroids in Type 2 Inflammatory Diseases

1 min

Type 2 Inflammation

Dr. Evan Dellon highlights potential risks with cumulative use of steroids for treatment of various coexisting type 2 inflammatory diseases.

Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Chronic Inflammatory Diseases

expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

15 min

Dermatology

Type 2 inflammatory mechanisms and key type 2 cytokines in the pathogenesis of atopic dermatitis – Presentation from the ADVENT symposium at ISID 2023

<b>Type</b> <b>2</b> <b>Inflammation</b> and Neuroimmune Axis Dysregulation in AD, PN, and CSU

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

2 min

Gastroenterology

Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ItalyChange country/region